The ICOPE trial is a comparative, multicentre, parallel-arm, open-label, randomised intervention trial, comparing the effectiveness of the global ICOPE strategy against usual care provided by the general practitioner.
The ICOPE strategy aims to strengthen the 6 essential functions (mobility, cognition, mental health, vision, hearing, and nutrition/vitality) and to prevent the loss of autonomy. The intervention lasts for 3 years, followed by a 2-year extension phase during which all study participants (1,000 individuals aged 70 and over in France starting from 2024) will receive the full ICOPE intervention (repeated screening, in-depth assessment, personalised prevention and care intervention, and follow-up).
This trial is currently the largest trial aiming to demonstrate the effectiveness of the ICOPE programme, and it is expected to have a global impact. In order to help health policy makers widely disseminate ICOPE, the trial will evaluate the socio-economic impact of the intervention.
This trial will also help build a biobank that will validate the biomarkers identified in the work carried out in pillar 2 of the IHU.
